1. Matsumae T*, Kodama T*, Tahata Y, Myojin Y, Doi A, Nishio A, Yamada R, Nozaki Y, Oshita M, Hiramatsu N, Morishita N, Ohkawa K, Hijioka T, Sakakibara M, Doi Y, Kakita N, Yakushijin T, Sakamori R, Hikita H, Tatsumi T, Takehara T. Thrombospondin-2 as a predictive biomarker for hepatocellular carcinoma after hepatitis C virus elimination by direct-acting antiviral. Cancers 2023 Jan 11;15(2):463. doi: 10.3390/cancers15020463. PMID: 36672412 (* These authors contributed equally)
2. Murai H*, Kodama T*, Maesaka K, Tange S, Motooka D, Suzuki Y, Shigematsu Y, Inamura K, Mise Y, Saiura A, Ono Y, Takahashi Y, Kawasaki Y, Iino S, Kobayashi S, Idogawa M, Tokino T, Hashidate-Yoshida T, Shindou H, Miyazaki M, Imai Y, Tanaka S, Mita E, Ohkawa K, Hikita H, Sakamori R, Tatsumi T, Eguchi H, Morii E, Tatsumi T, Takehara T. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology 2022 May 14. doi: 10.1002/hep.32573. Online ahead of print. (* These authors contributed equally)
3. Kodama T$, Kodama M, Jenkins NA, Copeland NG, Chen HJ, Wei Z*. Ring Finger Protein 125 is an Anti-proliferative Tumor Suppressor in Hepatocellular Carcinoma. Cancers 2022 May 24;14(11):2589. ($ Co-corresponding authors)
4. Matsumae T*, Kodama T*, Myojin Y, Maesaka K, Sakamori R, Takuwa A, Oku K, Motooka D, Sawai Y, Oshita M, Nakabori T, Ohkawa K, Miyazaki M, Tanaka S, Mita E, Tawara S, Yakushijin T, Nozaki Y, Hagiwara H, Tahata Y, Yamada R, Hikita H, Tatsumi T, Takehara T. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy. Cancers (Basel). 2022 Jul 11;14(14):3367. doi: 10.3390/cancers14143367. (* These authors contributed equally)
5. Kodama T, Takehara T. Is it a prime time for germline genetic testing for hepatocellular carcinoma? Hepatology 2023 Jan 3. doi: 10.1097/HEP.0000000000000033. Online ahead of print. PMID: 36626621.